News

Pawel Swieboda joins FIPRA as Special Advisor on Brain Health Policy

We are delighted to announce that Pawel Swieboda has joined FIPRA as Special Advisor on brain health policy.

With a career spanning high-profile positions in science, research, government, and think-tank leadership, Pawel brings a wealth of expertise and visionary leadership to FIPRA.

Pawel’s professional journey reflects his commitment to excellence and innovation. As Director General of the Human Brain Project and the CEO of EBRAINS AISBL since May 2020, he has overseen one of the world’s most extensive research programs in brain science. His strategic acumen positioned the project prominently within the European and global scientific landscape. Furthermore, Pawel served as President of the EBRAINS Management Board.

Pawel previously served as the Deputy Head and Head of Research at the European Political Strategy Centre of the European Commission, where he was part of the institution’s Presidential Team. He actively contributed to shaping the EU’s Science, Research, and Innovation Performance as a member of the European Commission’s Sounding Board. Additionally, he lent his expertise to the Global Agenda Council on Europe of the World Economic Forum.

“I am very excited to join FIPRA as a Special Advisor, where I will contribute to the organisation’s efforts in assisting clients to shape their strategies and achieve optimal outcomes for patients and healthcare systems.”

Pawel Swieboda

Special Advisor, Brain Health Policy

Pawel is not just a leader in the realm of science and policy; he is also an advisor to European and global companies and policy organisations, and a member of the Strategic Council of the European Policy Centre.

He was awarded the Knight’s Cross of the Order of Polonia Restituta in 2014.

We are happy to have Pawel on board and look forward to working with him to engage in impactful dialogue with decision-makers, aiming to ensure optimal outcomes for patients and healthcare systems.

Let's talk!  
Make your
policy impact
with FIPRA